Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver

Leukemia Research

Volumn 27, Issue 6, 2003, Pages 547-555

  Ferrao, Petranel T ^a,b   Gonda, Thomas J ^b,c   Ashman, Leonie K ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c Bionomics Ltd   (Australia)

Author keywords

c Kit; D816V mutation; Differentiation; Mast cell; Megakaryocyte; Transformation

Indexed keywords

STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL GROWTH; CELL LINEAGE; CELL MATURATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; FETUS; FETUS LIVER; HEMATOPOIETIC CELL; IMMUNOCYTOCHEMISTRY; MAST CELL; MEGAKARYOCYTE; MOUSE; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, NUCLEAR; CELL DIFFERENTIATION; CELL DIVISION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; COLONY-FORMING UNITS ASSAY; DNA HELICASES; DNA-BINDING PROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; MAST CELLS; MEGAKARYOCYTES; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; TRANSFECTION;

EID: 0346035004     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00272-2     Document Type: Article

References (63)

1. Galli S.J., Zsebo K.M., Geissler E.N. The Kit ligand, stem cell factor. Adv. Immunol. 55:1994;1-96.
2. Ashman L.K. The biology of stem cell factor and its receptor c-Kit. Int. J. Biochem. Cell Biol. 31:1999;1037-1051.
3. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int. J. Biochem. Cell Biol. 31:1999;1053-1074.
4. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y.et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. U.S.A. 92:1995;10560-10564.
5. Buttner C., Henz B.M., Welker P., Sepp N.T., Grabbe J. Identification of activating c-Kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J. Invest. Dermatol. 111:1998;1227-1231.
6. Longley B.J. Jr., Tyrrell L., Lu S.Z., Ma Y.S., Langley K., Ding T.G.et al. Somatic c-Kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12:1996;312-314.
7. Longley B.J. Jr., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.Z.et al. Activating and dominant inactivating c-Kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1609-1614.
8. Dror Y., Leaker M., Caruana G., Bernstein A., Freedman M.H. Mastocytosis cells bearing a c-Kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis. Br. J. Haematol. 108:2000;729-736.
9. Sotlar K., Marafioti T., Griesser H., Theil J., Aepinus C., Jaussi R.et al. Detection of c-Kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol. Pathol. 53:2000;188-193.
10. Jordan J.H., Fritsche-Polanz R., Sperr W.R., Mitterbauer G., Fodinger M., Schernthaner G.H.et al. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and c-Kit mutation Asp816Val. Leuk. Res. 25:2001;627-634.
11. Ashman L.K., Ferrao P., Cole S.R., Cambareri A.C. Effects of mutant c-Kit in early myeloid cells. Leuk. Lymphoma. 37:2000;233-243.
12. Beghini A., Peterlongo P., Ripamonti C.B., Larizza L., Cairoli R., Morra E.et al. c-Kit mutations in core binding factor leukemias. Blood. 95:2000;726-727.
13. Ning Z.Q., Li J., Arceci R.J. Activating mutations of c-Kit at codon 816 confer drug resistance in human leukemia cells. Leuk. Lymphoma. 41:2001;513-522.
14. Hongyo T., Li T., Syaifudin M., Baskar R., Ikeda H., Kanakura Y.et al. Specific c-Kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 60:2000;2345-2347.
15. Tian Q., Frierson H.F. Jr., Krystal G.W., Moskaluk C.A. Activating c-kit gene mutations in human germ cell tumors. Am. J. Pathol. 154:1999;1643-1647.
16. Worobec A.S., Semere T., Nagata H., Metcalfe D.D. Clinical correlates of the presence of the Asp816Val c-Kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer. 83:1998;2120-2129.
17. Sperr W.R., Walchshofer S., Horny H.P., Fodinger M., Simonitsch I., Fritsche-Polanz R.et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-Kit mutation Asp-816 to Val. Br. J. Haematol. 103:1998;740-749.
18. Akin C., Kirshenbaum A.S., Semere T., Worobec A.S., Scott L.M., Metcalfe D.D. Analysis of the surface expression of c-Kit and occurrence of the c-Kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol. 28:2000;140-147.
19. Fritsche-Polanz R., Jordan J.H., Feix A., Sperr W.R., Sunder-Plassmann G., Valent P.et al. Mutation analysis of c-Kit in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 113:2001;357-364.
20. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U.et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-Kit product. J. Clin. Invest. 92:1993;1736-1744.
21. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S.et al. Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580.
22. Taniguchi M., Nishida T., Hirota S., Isozaki K., Ito T., Nomura T.et al. Effect of c-Kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 59:1999;4297-4300.
23. Lasota J., Jasinski M., Sarlomo-Rikala M., Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 154:1999;53-60.
24. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D.et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:2001;1052-1056.
25. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S.et al. Safety and efficacy of Imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 358:2001;1421-1423.
26. Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H.et al. The c-Kit mutation causing human mastocytosis is resistant to STI571 and other Kit kinase inhibitors kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 99:2002;1741-1744.
27. Frost M.J., Ferrao P.T., Hughes T.P., Ashman L.K. Juxtamembrane mutanat V560GKit is more sensitive to Imatinib (STI571) compared to wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant. Mol. Cancer Ther. 1:2002;1105-1114.
28. Kitayama H., Kanakura Y., Furitsu T., Tsujimura T., Oritani K., Ikeda H.et al. Constitutively activating mutations of c-Kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. 85:1995;790-798.
29. Kitayama H., Tsujimura T., Matsumura I., Oritani K., Ikeda H., Ishikawa J.et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-Kit receptor tyrosine kinase. Blood. 88:1996;995-1004.
30. Piao X., Bernstein A. A point mutation in the catalytic domain of c-Kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood. 87:1996;3117-3123.
31. Ferrao P., Gonda T.J., Ashman L.K. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. Blood. 90:1997;4539-4552.
32. Tsujimura T., Furitsu T., Morimoto M., Kanayama Y., Nomura S., Matsuzawa Y.et al. Substitution of an aspartic acid results in constitutive activation of c-Kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int. Arch. Allergy Immunol. 106:1995;377-385.
33. Hashimoto K., Tsujimura T., Moriyama Y., Yamatodani A., Kimura M., Tohya K.et al. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am. J. Pathol. 148:1996;189-200.
34. Piao X., Paulson R., van der Geer P., Pawson T., Bernstein A. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. U.S.A. 93:1996;14665-14669.
35. Chian R., Young S., Danilkovitch-Miagkova A., Ronnstrand L., Leonard E., Ferrao P.et al. Phosphatidylinositol-3-kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood. 98:2001;1365-1373.
36. Ning Z.Q., Li J., Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood. 97:2001;3559-3567.
37. Yarden Y., Kuang W.J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J.et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6:1987;3341-3351.
38. Aylett GCSR, Caruana, G, Ashman, LK. Specificity and functional effects of mAb to c-Kit protein (SCF receptor). In: Schlossman SFBL, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, et al., editors. Leukocyte typing V - white cell differentiation antigens. Oxford: Oxford University Press; 1995. p. 1917-20.
39. Gonda T.J., Macmillan E.M., Townsend P.V., Hapel A.J. Differentiation state and responses to hematopoietic growth factors of murine myeloid cells transformed by Myb. Blood. 82:1993;2813-2822.
40. Ferrao P., Macmillan E.M., Ashman L.K., Gonda T.J. Enforced expression of full length c-Myb leads to density-dependent transformation of murine haemopoietic cells. Oncogene. 11:1995;1631-1638.
41. McNeil H.P., Frenkel D.P., Austen K.F., Friend D.S., Stevens R.L. Translation and granule localization of mouse mast cell protease-5. Immunodetection with specific antipeptide Ig. J. Immunol. 149:1992;2466-2472.
42. Karnovsky MJ, Roots LA. A direct coloring tricholine method for cholinesterases. J Histochem Cytochem 1964;12:219-21.
43. Yam L.T., Li C.Y., Crosby W.H. Cytochemical identification of monocytes and granulocytes. Am. J. Cytochem. Proc. 55:1971;283-290.
44. Lev S., Blechman J., Nishikawa S., Givol D., Yarden Y. Interspecies molecular chimeras of Kit help define the binding site of the stem cell factor. Mol. Cell. Biol. 13:1993;2224-2234.
45. Martin F.H., Suggs S.V., Langley K.E., Lu H.S., Ting J., Okino K.H.et al. Primary structure and functional expression of rat and human stem cell factor DNAs. Cell. 63:1990;203-211.
46. Moriyama Y., Tsujimura T., Hashimoto K., Morimoto M., Kitayama H., Matsuzawa Y.et al. Role of aspartic acid 814 in the function and expression of c-Kit receptor tyrosine kinase. J. Biol. Chem. 271:1996;3347-3350.
47. Broudy V.C. Stem cell factor and hematopoiesis. Blood. 90:1997;1345-1364.
48. Hu Y.L., Ramsay R.G., Kanei-Ishii C., Ishii S., Gonda T.J. Transformation by carboxyl-deleted Myb reflects increased transactivating capacity and disruption of a negative regulatory domain. Oncogene. 6:1991;1549-1553.
49. McCormack M.P., Gonda T.J. Expression of activated mutants of the human interleukin-3/interleukin-5/granulocyte-macrophage colony-stimulating factor receptor common beta subunit in primary hematopoietic cells induces factor-independent proliferation and differentiation. Blood. 90:1997;1471-1481.
50. Briddell R.A., Bruno E., Cooper R.J., Brandt J.E., Hoffman R. Effect of c-Kit ligand on in vitro human megakaryopoiesis. Blood. 78:1991;2854-2859.
51. Broudy V.C., Lin N.L., Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin 11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 85:1995;1719-1726.
52. Mayrhofer G., Gadd S.J., Spargo L.D., Ashman L.K. Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues. Immunol. Cell. Biol. 65:1987;241-250.
53. Irani A.M., Nilsson G., Miettinen U., Craig S.S., Ashman L.K., Ishizaka T.et al. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood. 80:1992;3009-3021.
54. Valent P., Spanblochl E., Sperr W.R., Sillaber C., Zsebo K.M., Agis H.et al. Induction of differentiation of mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/Kit ligand in long-term culture. Blood. 80:1992;2237-2245.
55. cip1. Mol. Cell. Biol. 17:1997;5598-5611.
56. cip1. Mol. Cell. Biol. 17:1997;5588-5597.
57. Caruana G., Cambareri A.C., Gonda T.J., Ashman L.K. Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement. Oncogene. 16:1998;179-190.
58. Tsujimura T., Hashimoto K., Kitayama H., Ikeda H., Sugahara H., Matsumura I.et al. Activating mutation in the catalytic domain of c-Kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood. 93:1999;1319-1329.
59. Afonja O., Amorosi E., Ashman L., Takeshita K. Multilineage involvement and erythropoietin-"independent" erythroid progenitor cells in a patient with systemic mastocytosis. Ann. Hematol. 77:1998;183-186.
60. Cole S.R., Aylett G.W., Harvey N.L., Cambareri A.C., Ashman L.K. Increased expression of c-Kit or its ligand steel factor is not a common feature of adult acute myeloid leukaemia. Leukemia. 10:1996;288-296.
61. Ruley H.E. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature. 304:1983;602-606.
62. Land H., Parada L.F., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 304:1983;596-602.
63. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.